Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy
10.3760/cma.j.cn371439-20221115-00021
- VernacularTitle:胸部放疗联合免疫治疗时代肺炎发生的影响因素
- Author:
Huayu HUANG
1
;
Hongyun GONG
;
Qibin SONG
Author Information
1. 武汉大学人民医院肿瘤中心，武汉 430060
- Keywords:
Thoracic radiotherapy;
Immunotherapy;
Pneumonitis
- From:
Journal of International Oncology
2023;50(2):102-106
- CountryChina
- Language:Chinese
-
Abstract:
The combination of thoracic radiotherapy and immunotherapy is increasingly widely used in clinical practice, which not only brings survival benefits but also increases the incidence of pneumonitis. The occurrence of pneumonitis affects the subsequent immunotherapy and can be life-threatening in severe cases. The occurrence and severity of pneumonitis after combination therapy depends on a variety of factors, including patient's age, physical strength, pulmonary function, race, combination therapy mode, radiotherapy dose parameters, type of immune checkpoint inhibitor, history of checkpoint inhibitor-related pneumonitis or radiation pneumonitis, serum indexes and so on. At present, further research is needed to find out the influencing factors of the occurrence and severity of pneumonitis attributed to combined therapy, so as to better avoid, predict, identify and treat related pneumonitis in clinical practice.
